NEW YORK, Oct. 20 (GenomeWeb News) - Affymetrix said today that it has signed two separate deals granting partners access to its GeneChip microarray technology.
Under the first, diagnostics firm Biomerieux will have the non-exclusive right to use the GeneChip technology in the development of tests for virulence factors, bacterial strain typing, and sepsis diagnosis. This arrangement, which expands an ongoing collaboration between the companies, also gives Biomerieux rights to use the technology to develop assays for hepatitis C, as well as respiratory and central nervous system infectious panels.
Affymetrix will receive upfront and milestone payments in exchange for the GeneChip technology, as well as royalties on product sales.
Under the second deal, Paradigm Genetics will begin offering its customers microarray processing services using the GeneChip technology. Paradigm will also have the right to use certain Affymetrix technologies for its internal research efforts.
Financial details of the Paradigm arrangement were not disclosed.